Pressemitteilung BoxID: 733126 (4SC AG)
  • 4SC AG
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried
  • Ansprechpartner
  • Chad Rubin
  • +1 (646) 378-2947

Dr Susanne Danhauser-Riedl joins 4SC as Chief Medical Officer to strengthen management and clinical development team

(PresseBox) (Martinsried, ) 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, today announced the appointment of Dr Susanne Danhauser-Riedl as the Company's Chief Medical Officer (CMO). Dr Danhauser-Riedl will take over management of clinical development at 4SC AG from 1 April 2015 and thus assume responsibility for the further clinical development of the Company's oncology pipeline, including the compounds resminostat, 4SC-202 and 4SC-205. As Chief Medical Officer, she will report directly to Management Board Member and Chief Development Officer (CDO) & Chief Scientific Officer (CSO) Dr Daniel Vitt.

Dr Susanne Danhauser-Riedl is a medical doctor and has long standing experience in the fields of haematology and oncology. She has over 20 years of management experience both in research and clinical practice and in the fields of Medical Affairs and clinical development in the pharmaceutical industry. Prior to joining 4SC, she spent almost ten years at the pharmaceutical company GlaxoSmithKline GmbH & Co. KG (GSK). At GSK she held responsibility for the complete Life Cycle Management including clinical development of the oncology portfolio in Germany serving as Medical Head Haematology/Oncology and, from 2012, as Medical Head Haematology/Head Regional Medical Advisors. Before joining GSK, Dr Danhauser-Riedl spent four years in the field of Medical Affairs at MedacSchering Onkologie GmbH, most recently as Head of Medical Affairs and Drug Safety. Before that she worked over twelve years as a medical doctor and research scientist in haematology/oncology at a number of university hospitals in Munich, Germany. Her positions there included Head of Immunophenotyping at the Specialist Leukaemia Diagnostics Lab (University Hospital, LMU Munich, Großhadern campus) and Head of the Immunocytology Lab within the Department of Haematology (University Hospital, LMU Munich, City campus).

Dr Danhauser-Riedl studied medicine at the University of Regensburg and at Technische Universität München (TUM), Germany and has the European Diploma for Pharmaceutical Medicine (ECPM, University of Basel, Switzerland). She is a member of the German Society for Haematology and Oncology (DGHO), the German Society for Pharmaceutical Medicine (DGPharMed) and the American Society of Clinical Oncology (ASCO).

Enno Spillner, Chief Executive Officer and Chairman of the Management Board of 4SC AG commented: "We are very pleased to be able to bring Dr Danhauser-Riedl on board as our Chief Medical Officer. With her extensive and long-standing experience in research, clinical practice and the pharmaceutical industry, she provides broad-based support for our plans to press on with the further clinical development of our promising oncology pipeline and thus establish a strong portfolio of high-value cancer therapies."

Dr Susanne Danhauser-Riedl added: "I look forward to my exciting new role at 4SC. I believe 4SC possesses an extremely attractive oncology portfolio - not least because epigenetics is a very interesting research field within medicine. Together with the R&D team of 4SC, we want to advance the drug candidates swiftly, first and foremost to provide patients with a significant clinical benefit."

Cautionary statement regarding forward-looking statements

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.

For more information please visit


The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 66 employees (57 FTEs) at 31 December 2014. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.